2026

A new, machine learning-based approach to metastatic neuroendocrine tumors of unknown origin
Lü J, Amin T, Clauditz T, Steinkraus K, Buchstab O, Huber S, Izbicki J, Fründt T, Schrader J, Werner R, Schmitz R
J NEUROENDOCRINOL. 2026;38(2):e70134.

2025

Minimally Invasive Resection of Occult Insulinomas-Experience from an ENETS Centre of Excellence and Review of the Literature
Ritter A, Ockenga F, Steinkraus K, Poppinga J, von Kroge P, Amin T, Viol F, Fründt T, Nickel F, Hackert T, Nießen A
CANCERS. 2025;17(23):3857.

2024

Visceral Medicine:The View of GI
Huebener P, Amin T, Lohse A
VISC MED. 2024;39(6):163-165.

Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?
Schmidt B, Leiderer M, Amin T, Viol F, Huber S, Henes F, Schrader J
ENDOCRINE. 2024;83(2):511-518.

Perioperative management of pancreatic exocrine insufficiency-evidence-based proposal for a paradigm shift in pancreatic surgery
Stern L, Schuette M, Goetz M, Nitschke C, Bardenhagen J, Scognamiglio P, Stüben B, Calavrezos L, Amin T, Heumann A, Lohse A, de Heer G, Izbicki J, Uzunoglu F
HPB. 2024;26(1):117-124.

2023

Cancer associated fibroblasts induce proliferation and therapeutic resistance to everolimus in neuroendocrine tumors through STAT3 activation
Amin T, Viol F, Krause J, Fahl M, Eggers C, Awwad F, Schmidt B, Benten D, Ungefroren H, Fraune C, Clauditz T, Sauter G, Izbicki J, Lohse A, Huber S, Schrader J
NEUROENDOCRINOLOGY. 2023;113(5):501-518.

2022

Metabolic Syndrome Is Associated with Impaired Survival after Surgery for Pancreatic Neuroendocrine Tumors
Awwad F, Ozga A, Amin T, Schlueter C, Kailani S, Perez D, Wolter S, Sauter G, Izbicki J, Lohse A, Schrader J
NEUROENDOCRINOLOGY. 2022;112(12):1225-1236.

The Patient's Point of View: COVID-19 and Neuroendocrine Tumor Disease
Krug S, Khosravian M, Weissbach J, George K, Damm M, Garbe J, Walldorf J, Reuken P, Amin T, Siebenhüner A, Rosendahl J, Gress T, Michl P, Schrader J, Rinke A
CANCERS. 2022;14(3):.

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy
Viol F, Sipos B, Fahl M, Clauditz T, Amin T, Kriegs M, Nieser M, Izbicki J, Huber S, Lohse A, Schrader J
CELL ONCOL. 2022;45(6):1401-1419.

2020

Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas
Fraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Büscheck F, Amin T, Viol F, Fehrle W, Dum D, Höflmayer D, Burandt E, Clauditz T, Perez D, Izbicki J, Wilczak W, Sauter G, Steurer S, Schrader J
ENDOCR PATHOL. 2020;31(2):182-189.

Letzte Aktualisierung aus dem FIS: 21.07.2026 - 05:01 Uhr